TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy.
A549 Cells
Animals
Dendritic Cells
/ metabolism
Flow Cytometry
Humans
Imiquimod
/ chemistry
Immunotherapy
/ methods
Killer Cells, Natural
/ drug effects
Leukocytes, Mononuclear
/ metabolism
Male
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Nanomedicine
/ methods
Nanoparticles
/ chemistry
Toll-Like Receptor 7
/ agonists
Toll-Like Receptor 8
/ agonists
ADCC
NK cell
TLR7/8 agonist
cancer immunotherapy
nanomedicine
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
pubmed:
10
5
2020
medline:
8
6
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
Activated natural killer (NK) cells can kill malignant tumor cells via granule exocytosis and secretion of IFN-γ, a key regulator of the TH1 response. Thus, mobilization of NK cells can augment cancer immunotherapy, particularly when mediated through antibody-dependent cellular cytotoxicity (ADCC). Stimulation of toll-like receptor (TLR)7/8 activity in dendritic cells promotes pro-inflammatory cytokine secretion and costimulatory molecule upregulation, both of which can potentiate NK cell activation. However, currently available TLR7/8 agonists exhibit unfavorable pharmacokinetics, limiting their
Identifiants
pubmed: 32383885
doi: 10.1021/acs.molpharmaceut.0c00271
doi:
Substances chimiques
Toll-Like Receptor 7
0
Toll-Like Receptor 8
0
Imiquimod
P1QW714R7M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM